Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 at 8:40 am PT (11:40 am ET) at the Encore at Wynn Las Vegas in Las Vegas, Nevada, and at the UBS Global Healthcare Conference on Wednesday, May 24, 2017 at 10:00 am ET at the Grand Hyatt New York in New York City.
A live audio webcast of each presentation will be available on the Investors section of the company’s website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the lives
of patients who have limited or inadequate treatment options. Based on
Nobel Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
debilitating diseases. Founded in 2002, Alnylam is delivering on a bold
vision to turn scientific possibility into reality, with a robust
discovery platform and deep pipeline of investigational medicines,
including three product candidates that are in late-stage development or
will be in 2017. Looking forward, Alnylam will continue to execute on
its “Alnylam 2020” strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable pipeline
of RNAi-based medicines. For more information about our people, science
and pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170510005015/en/
Contacts:
Christine Regan Lindenboom,
617-682-4340
(Investors and Media)
or
Josh Brodsky,
617-551-8276
(Investors)